Provided are anti-idiotype antibodies that specifically recognize anti-BCMA antibody moieties, in particular, anti-BC-MA antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of antiidiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-BCMA CAR T cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.

The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Provided herein are single-chain polypeptides and multi-chain polypeptides that bind specifically to CD3 epsilon (CD3ε). Also provided herein are anti-idiotypic antibodies that bind specifically to any of the antigen-binding domains described herein.

The invention provides improved methods for detecting anti-BCMA CAR expression on T cells. The invention generally provides antibodies and antigen binding fragments thereof, conjugates thereof, and methods of using the same to detect, determine, or measure CAR T cells and/or CAR expression on one or more T cells.

Herein is reported a method for determining the epitope of an antibody specifically binding to a therapeutic antibody comprising the steps of a) incubating a sample, which comprises serum and the antibody specifically binding to a therapeutic antibody, separately with i) at least a Fab fragment of the therapeutic antibody, and ii) at least a Fab fragments of the therapeutic antibody in which the HVRs forming a paratope have been replaced with germline sequences, and detecting the binding or non-binding of the antibody specifically binding to a therapeutic antibody to the at least a Fab fragment in any of i) to ii), and b) determining the epitope of the antibody specifically binding to a therapeutic antibody to be in the at least one HVR that has been replaced in ii) if binding is detected in i) and non-binding is detected in ii).

The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.

The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Provided are compositions and methods for improving tumor penetrability of anti-tumor antibodies or conjugates thereof. The method comprises administering to an individual in need of treatment an anti-idiotypic antibody in addition to the anti-tumor antibody or conjugate. Examples are provided for anti-HER2 antibodies and anti-idiotypic antibodies that are directed to the anti-HER2 antibodies.

Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.

This disclosure provides modified B cells which produce heterologous antibodies and co-express cargo proteins. The modified B cells may be stimulated by binding of a cognate antigen to the heterologous antibodies. The B cells may be reduced or eliminated by contacting the heterologous antibody with an anti-idiotypic antibody. Methods of making, and using the modified B cells for prophylaxis and therapy for a variety of conditions are provided. The B cells are modified at an IgH locus, an IgK locus, and combinations thereof. Modified B cells maintain allelic exclusion.